文献速递肿瘤 PET/CT骨显像与常规 SPECT核素与放射性配体治疗

[18F]FDG PET/CT 用于早期起病风湿性多肌痛阿巴西普治疗的疗效评估

[18F]FDG PET/CT for therapeutic assessment of Abatacept in early-onset polymyalgia rheumatica.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-12-14

本研究为 ALORS 试验的辅助研究,评估 [18F]FDG PET/CT 在早期起病风湿性多肌痛患者中评价阿巴西普(ABA)一线治疗疗效的价值。患者基线和治疗 12 周后行 [18F]FDG PET/CT,结果显示 ABA 组与安慰剂组在所有感兴趣区的 SUVmax 无显著差异,仅在无糖皮质激素补救的亚组中左胸锁关节 ROI 的 SUVmax 在 ABA 组下降(-0.8)而安慰剂组升高(+0.6),差异有统计学意义(p 0.047)。

要点

  • 12 周时 ABA 组与安慰剂组在所有 ROI 的 SUVmax 无显著差异。
  • 无 GC 补救亚组中左胸锁关节 ROI 的 SUVmax 变化 ABA 组 -0.8 对比安慰剂组 +0.6(p 0.047)。
  • 联合定性评分在直接比较和 GC 补救亚组分析中均无显著差异。

核心结论

  • 与安慰剂相比,ABA 治疗后 [18F]FDG PET/CT 在 PMR 常受累解剖区域的摄取未显著下降,结果与临床-生物学疗效评估一致。

研究设计与样本

  • 本研究为 ALORS 试验(阿巴西普治疗早期起病风湿性多肌痛研究)的辅助研究,评估 ABA 对比安慰剂在 12 周时能否在不使用糖皮质激素的情况下达到低疾病活动度(CRP PMR-AS ≤10)。
  • 患者在基线和治疗 12 周后接受 [18F]FDG PET/CT 检查。
  • 采用 CRP PMR-AS、ESR PMR-AS、Clin PMR-AS 和 CRP 插补(Imput-CRP)PMR-AS 评估治疗反应。
  • 采用最大标准化摄取值(SUVmax)定量评分及根据肝脏摄取制定的联合定性评分(Leuven、Leuven/Groningen 和 Besançon 评分)评估 PMR 常受累感兴趣区(ROI)的 [18F]FDG 摄取。
  • 采用 Student t 检验评估 ABA 组与安慰剂组之间 W0 至 W12 的临床、生物学和 [18F]FDG 摄取变化差异,并按 GC 补救进行亚组分析。

主要发现

  • 12 周时 ABA 组与安慰剂组在所有 ROI 的 SUVmax 均无显著差异。
  • 按 GC 给药进行亚组分析显示,无 GC 补救时 ABA 组左胸锁关节 ROI 的 SUVmax 下降(-0.8),安慰剂组升高(+0.6),差异有统计学意义(p 0.047)。
  • 其他结果未显示 ABA 组与安慰剂组之间有任何显著差异。
  • 根据联合定性评分,直接比较分析和按 GC 补救进行的亚组分析中 ABA 组与安慰剂组均无显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Evaluate the benefit of 2-deoxy-2-[18F]-fluoro-D-glucose ([18F] FDG) positron emission tomography/computed tomography (PET/CT) for the therapeutic assessment of Abatacept (ABA) as first-line therapy in early-onset polymyalgia rheumatica (PMR) patients. METHODS: This was an ancillary study of ALORS trial (Abatacept in earLy Onset polymyalgia Rheumatica Study) assessing the ability of ABA versus placebo to achieve low disease activity (C-Reactive Protein PMR activity score (CRP PMR-AS) ≤ to 10) without glucocorticoid (GC) at week 12 in patients with early-onset PMR. The patients underwent [18F] FDG PET/CT at baseline and after 12 weeks of treatment. Responses to treatments were evaluated according to CRP PMR-AS, Erythrocyte Sedimentation Rate (ESR) PMR-AS, Clin PMR-AS, and CRP-Imputed (Imput-CRP) PMR-AS. Quantitative score by maximal standardized uptake value (SUVmax) and combined qualitative scores according to liver uptake (Leuven, Leuven/Groningen, and Besançon Scores) were used for assessment of [18F] FDG uptake in regions of interest (ROI) usually affected in PMR. Student's t-test was applied to evaluate the clinical, biological, and [18F] FDG uptake variation difference in ABA and placebo groups between W0 and W12. Subgroup analysis by GC rescue was performed. RESULTS: At W12, there was no significant difference according to SUVmax between the ABA and the placebo groups in all ROI. Subgroup analysis according to GC administration demonstrated a significant (p 0.047) decrease in SUVmax within the left sternoclavicular joint ROI in the ABA group (- 0.8) compared to the placebo group (+ 0.6) without GC rescue. Other results did not reveal any significant difference between the ABA and placebo groups. According to combined qualitative scores, there was no significant difference between ABA and placebo groups for the direct comparison analysis and subgroup analysis according to GC rescue. CONCLUSION: [18F] FDG PET/CT uptake did not decrease significantly after ABA compared to placebo in anatomical areas usually affected in PMR patients. These results are correlated with the clinical-biological therapeutic assessment. CLINICAL TRIAL REGISTRATION: The study was approved by the appropriate ethics committee (CPP Sud-Est II Ref CPP: 2018-33), and all patients gave their written informed consent before study enrollment. The protocol was registered on Clinicaltrials.gov (NCT03632187).

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Allard B, Devauchelle-Pensec V, Saraux A, et al. [18F]FDG PET/CT for therapeutic assessment of Abatacept in early-onset polymyalgia rheumatica. Eur J Nucl Med Mol Imaging. 2023. PMID: 38095675. doi:10.1007/s00259-023-06557-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。